Monte Rosa Therapeutics GLUE

Dr. Markus Warmuth, M.D. has served as our President and Chief Executive Officer and a member of our board of directors since January 2020. Dr. Warmuth has also served as a Venture Partner at Versant Venture Management, LLC, a healthcare investment firm, from September 2019 to January 2024. From July 2018 to August 2019, he worked as an Entrepreneur-in-Residence for Third Rock Ventures, LLC, a venture capital firm. From October 2011 to May 2018, Dr. Warmuth was the Chief Executive Officer and, previously from August 2011 to October 2011, Chief Scientific Officer of H3 Biomedicine Inc., a drug development company. Dr. Warmuth has served as a member of the board of directors of IMV Inc., a clinical stage biopharmaceutical company, from November 2018 to September 2023, and Relay Therapeutics, a clinical stage precision medicine company, from July 2018 to August 2019. Dr. Warmuth has also previously served in multiple roles at the Novartis Institutes for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), including as the Director of Kinase Biology, Head of Oncology Pharmacology. While at Novartis, he and his teams were involved in the development of Ceritinib, Ribociclib, and Asciminib. He received an M.D. from Ludwig Maximilian University, Munich, Germany.

Dr. Filip Janku, M.D.,PhD has served as our Chief Medical Officer since June 2021. From February 2009 to May 2021, Dr. Janku served in various positions at The University of Texas MD Anderson Cancer Center, or MD Anderson, including Center Medical Director for MD Anderson's Clinical and Translational Research Center and Associate Professor in its Department of Investigational Cancer Therapeutics, where he focused his research on developing new cancer drugs, with an emphasis on personalized medicine. Dr. Janku has expertise in the innovative early-phase clinical development of new cancer drugs, with a special focus on proof-of-concept clinical studies of novel, biomarker-driven, personalized therapies. His work has been recognized with multiple awards, including the Emil Frei III Award for Excellence in Translational Research, the Sabin Family Fellow Award, the Khalifa Scholar Award, and the Sidney Kimmel Scholar Award. He has also authored or coauthored over 300 scientific articles in peer-reviewed journals. Dr. Janku received his M.D. and Ph.D. from Charles University in the Czech Republic.

Dr. Philip Nickson, J.D.,PhD has served as our Chief Business and Legal Officer since May 2024. From March 2022 to April 2024, Dr. Nickson served as our General Counsel. From March 2021 to March 2022, Dr. Nickson led our legal function serving as our Head of Legal Operations. From January 2012 to March 2021, Dr. Nickson served in various roles of increasing responsibility at Momenta Pharmaceuticals, acquired by Johnson and Johnson in October 2020, including most recently as Vice President of Intellectual Property and Associate General Counsel. From January 2006 to January 2012, Dr. Nickson served in various positions at the law firm Fish and Richardson, with a practice focusing on supporting small to mid-size biotech clients. Prior to practicing law, Dr. Nickson completed a post-doctoral research program at the Boston Biomedical Research Institute researching cardiomyocyte cell death. Dr. Nickson received his J.D. from Suffolk University and his Ph.D. from University of Manchester.

Dr. Andrew N. Schiff, M.D. has been a member of our board of directors since September 2020 and as our chairman since June 2023. Dr. Schiff serves as a Managing Partner of Aisling Capital, a venture capital firm, that he has been affiliated with since 1999. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine at the New York Presbyterian Hospital, where he currently maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff serves as a member of the board of directors of Aclaris Therapeutics, Inc., a publicly-traded pharmaceutical company, since 2017. Dr. Schiff received an M.D. from Cornell University Medical College, an M.B.A. from Columbia Business School, and a B.S. in neuroscience with honors from Brown University.

Ms. Christine Siu has been a member of our board of directors since December 2020. Ms. Siu is currently the Chief Executive Officer of BridgeBio Neuromuscular, a pharmaceutical company, and has held this role since January 2022. Previously, Ms. Siu served as the Chief Operating Officer in Residence of BridgeBio Pharma Inc., a pharmaceutical company, from January 2020 to January 2022, Chief Financial Officer of Eidos Therapeutics, Inc., a biopharmaceutical company from December 2017 to December 2019, Chief Operating Officer of Eidos Therapeutics, Inc. from April 2016 to December 2017, Chief Business Officer of The Bluefield Project to Cure Frontotemporal Dementia from 2014 to 2017, and as Senior Director of Corporate Development at Global Blood Therapeutics, Inc., a biopharmaceutical company, from 2012 to 2014. Ms. Siu also held positions at various private equity and venture capital firms, including Third Rock Ventures, LLC, Warburg Pincus LLC and Thomas, McNerney & Partners, LLC, where she invested in life sciences companies and served as a member of the board of directors of Bright Peak Therapeutics, Inc., a privately-held biotechnology company, from June 2021 to January 2025. Ms. Siu received an M.B.A. from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.

Dr. Kimberly L. Blackwell, M.D. has been a member of our board of directors since July 2020. Dr. Blackwell serves as the Chief Development Officer of Nucleus RadioPharma, a contract development and manufacturing organization, since September 2025. Dr. Blackwell served as Chief Executive Officer at Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from May 2022 to November 2024. Dr. Blackwell formerly served as Chief Medical Officer of Tempus Labs, Inc., a biotechnology company, from March 2020 to May 2022 and as Vice President of Early Phase Oncology and Immuno-oncology at Eli Lilly and Company, a global pharmaceutical company, from March 2018 to March 2020. From 2012 to 2018, Dr. Blackwell served as Director of the Women's Cancer Program, Professor of Medicine, and Associate Director for Strategic Relations at the Duke Cancer Institute where she led the clinical development teams for promising early stage therapeutics. Dr. Blackwell serves as a member of the board of directors of Century Therapeutics, Inc., a publicly-traded biotechnology company, since June 2021 and Incyclix Bio, LLC, a privately-held oncology therapeutics company, since December 2025. Dr. Blackwell formerly served as a member of the board of directors of Zentalis Pharmaceuticals, Inc., a publicly-traded clinical-stage biopharmaceutical company, from July 2020 to November 2024. Dr. Blackwell received an M.D. from the Mayo Clinic College of Medicine and Science and a B.A. in bioethics from Duke University.

Dr. Anthony M. Manning, PhD has been a member of our board of directors since July 2023. Dr. Manning is a seasoned drug discoverer with a 30-year career in the pharmaceutical and biotechnology industry during which he led the discovery and development of multiple therapeutics, contributing to the approval of three drugs for the treatment of autoimmune diseases. Dr. Manning also serves as a Board Director for Cyrus Biotechnology, a privately-held biotechnology company, is Chairman of the Institute for Biomedical Entrepreneurship, a non-profit that mentors and supports biotech founders and innovators, and is an advisor to several biotechnology companies and to the Harvard Medical School Therapeutics Initiative and the Blavatnik Biomedical Accelerator at Harvard. Previously, Dr. Manning served as a member of the Board of Directors of Palatin Technologies Inc., a publicly-traded biopharmaceutical company, from September 2017 until June 2025. As the former Chief Scientific Officer at Momenta Pharmaceuticals, a biopharmaceutical company, from 2018 to March 2021, Dr. Manning built a pipeline of first-in-class therapeutics, leading to the company's acquisition by Johnson & Johnson for $6.5 billion in 2020. Earlier, Dr. Manning spearheaded research and drug discovery at Biogen Idec, a biopharmaceutical company, from 2007 to 2011, at Roche Pharmaceuticals, the pharmaceutical division of research healthcare company Roche Holding AG, from 2002 to 2007, and at Pharmacia Corp, a pharmaceutical company that merged with Pfizer in 2003, from 2000 to 2002. Dr. Manning's contributions include over 120 scientific publications and patents in autoimmune diseases research, drug discovery, and novel therapeutics.

Dr. Jan Skvarka, M.B.A.,PhD has been a member of our board of directors since March 2023. Dr. Skvarka serves as the Chairman of DEM BioPharma, Inc, a privately held immune-oncology company, since March 2022 and as a member of the board of directors of Zentalis Pharmaceuticals, Inc., a publicly-traded clinical-stage biopharmaceutical company, since September 2022. He previously served as the Executive Chairman of GentiBio, Inc., a privately held biotherapeutics company, from June 2022 to November 2022. From September 2019 to November 2021, Dr. Skvarka was the President and Chief Executive Officer and a member of the board of directors of Trillium Therapeutics, Inc., a publicly-traded, clinical-stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, propelling Trillium from a $16 million market capitalization to a $2.3 billion acquisition by Pfizer Inc. in two years. From 2014 to January 2019, Dr. Skvarka served as the President and Chief Executive Officer of Tal Medical, a private clinical-stage neuromodulation company, where he developed and executed the company's strategy, built an accomplished leadership team, and oversaw its clinical development program. He also held roles of increasing responsibility at Bain & Company, most recently as a Partner, and was a leading member of Bain Healthcare Practice, with a focus on life sciences. Dr. Skvarka received a BS in business administration and a PhD in economics from the University of Economics in Bratislava, Slovakia, and an MBA from Harvard Business School.

Dr. Ali Behbahani, M.B.A.,M.D. has been a member of our board of directors since April 2020. Dr. Behbahani joined New Enterprise Associates, Inc., a venture capital firm, in 2007 and is a Partner and Co-Head of Healthcare. Prior to joining New Enterprise Associates, Inc., Dr. Behbahani served as a consultant in business development at The Medicines Company, a pharmaceutical company, a Venture Associate at Morgan Stanley, a multinational investment bank and financial services company, and a Healthcare Investment Banking Analyst at Lehman Brothers, a global financial services firm, from 1998 to 2000. Dr. Behbahani serves as a member of the board of directors of SpyGlass Pharma, Inc., a publicly-traded biopharmaceutical company, since May 2019, Nkarta, Inc., a publicly-traded biotechnology company, since August 2015, Black Diamond Therapeutics, Inc., a publicly-traded biopharmaceutical company, since December 2018, CRISPR Therapeutics AG, a publicly-traded biotechnology company, since March 2015, Korro Bio, Inc., a publicly-traded biotechnology company, since August 2019, and Arcellx, Inc., a publicly-traded biotechnology company, since February 2015. Dr. Behbahani formerly served as a member of the board of directors of Adaptimmune Therapeutics plc, a publicly-traded biopharmaceutical company, from September 2014 to November 2025, CVRx, Inc., a publicly-traded medical device company, from July 2013 to September 2024, Nevro Corp., a publicly-traded global medical device company, from August 2014 to March 2019, Oyster Point Pharma, Inc., a privately-held biopharmaceutical company, from July 2017 to January 2023, Genocea Biosciences, Inc., a publicly-traded biopharmaceutical company, from February 2018 to May 2022, Minerva Surgical Inc., a privately-held biotechnology company, from May 2011 to January 2024, and Marker Therapeutics, Inc., a publicly-traded biopharmaceutical company, until 2017. Dr. Behbahani received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University.

Dr. Eric A Hughes, M.D.,PhD has been a member of our board of directors since December 2024. Dr. Hughes serves as Executive Vice President, Global R&D and Chief Medical Officer at Teva Pharmaceuticals Industries Ltd., a role he has held since August 2022. Prior to joining Teva Pharmaceuticals, from 2021 to 2022, Dr. Hughes was Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals. From 2015 to 2021, Dr. Hughes served as Global Development Unit Head for Immunology, Hepatology and Dermatology at Novartis, ultimately responsible for leading all clinical development activities and biostatistician talent across multiple therapeutic areas and for expanding development in China. Additionally, between 2020 and 2021, during the COVID-19 pandemic, Dr. Hughes also served as Co-Chair of the Therapeutics Clinical Working Group for the Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership at the National Institutes of Health. From 2010 to 2015, Dr. Hughes held several executive and senior positions at Bristol Myers-Squibb, including Head of Virology, Fibrotic Diseases, Genetically Defined Diseases, Autoimmunity, and Cardiology Discovery Medicine, Exploratory Clinical & Translational Research. Dr. Hughes received his MD and Ph.D. from Yale School of Medicine.

Ms. Jennifer Champoux has served as our Chief Operating Officer since May 2024. Ms. Champoux joined Monte Rosa on March 2021 as Senior Vice President of Operations. From March 2023 to May 2024, Ms. Champoux served as Chief People and Operations Officer. Prior to joining Monte Rosa, from May 2019 to March 2021, Ms. Champoux was Executive Director of Operations at H3 Biomedicine where she led the operations, communications, and finance operations teams. Prior to that, Ms. Champoux was a Director, Operations at H3 Biomedicine from June 2017 to May 2019. From February 2006 to May 2017, Ms. Champoux previously worked at Novartis Institutes for Biomedical Research and served in various roles of increasing responsibility, ultimately leading operations for the Discovery Chemistry group in Cambridge. Ms. Champoux started her career in several pharmaceutical development functions, including process chemistry, program management, and clinical operations at Merck and Array BioPharma. Ms. Champoux holds a B.S. in chemistry from University of Vermont and a M.S in organic chemistry from Indiana University.

Dr. Sharon Townson, PhD has served as our Chief Scientific Officer since May 2024. From December 2020 to April 2024, Dr. Townson served as our Chief Technology Officer. Dr. Townson originally joined Monte Rosa on July 2020 as Vice President, Biomolecular Sciences and brings expertise in molecular glues and targeted protein degradation technology platforms. Prior to joining Monte Rosa, Dr. Townson served as Executive Director of Platform Biology at Kymera Therapeutics from April 2019 to July 2020. Previously, from June 2013 to December 2018, Dr. Townson served in various leadership roles at Warp Drive Bio and was responsible for developing their novel molecular glue approach to target KRAS. Dr. Townson began her career at Pfizer as a structural biologist and holds a Ph.D. in structural biology and biochemistry from the University of Manchester Institute of Technology.

Dr. Chandra P. Leo, M.D. has been a member of our board of directors since September 2020. Dr. Leo has served as an Investment Advisor in the private equity team at HBM Partners AG, a Swiss healthcare investment company, since 2007. Between 1997 and 2007, Dr. Leo worked as a postdoctoral scientist at Stanford University, as a physician at the University Hospital Leipzig and as a principal at Wellington Partners, a venture capital firm. Dr. Leo currently serves as a director on the boards of Dren Bio Holdings LLC, Fore Biotherapeutics Inc., River 2 Renal Corp. and River 3 Renal Corp., all of which are privately-held biotechnology companies. Dr. Leo previously served as a member of the board of directors of other healthcare-focused firms, including Galecto, Inc. (now publicly traded as Damora Therapeutics, Inc.) and Longboard Pharmaceuticals, Inc. (acquired by Lundbeck in 2024). He received an M.D. from the Freie Universitat Berlin, an M.B.A. from INSEAD and an M.A.S. in medicines development from the University of Basel.

Effective April 3, 2026, Matthew Bowen, currently an employee of the Company, will serve as Corporate Controller and Principal Accounting Officer of the Company. Mr. Bowen, age 37, joined the Company's finance department following the Company's initial public offering in June 2021 to support the enhanced financial reporting and compliance requirements associated with operating as a public company. Since joining the Company, Mr. Bowen has served in roles of increasing responsibility over the past nearly five years, most recently as Director, Finance. Prior to joining the Company, Mr. Bowen spent seven years in the audit and assurance practice at Ernst & Young LLP, where he primarily worked on audits of large public companies. Mr. Bowen holds a Bachelor of Science and a Master's in Accounting from Bryant University and is a licensed Certified Public Accountant in the Commonwealth of Massachusetts.